Bristol-Myers Squibb Co
BMY
Company Profile
Business description
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
Contact
Route 206 and Province Line Road
Princeton
New JerseyNJ08543
USAT: +1 609 252-4621
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
34,100
Stocks News & Analysis
stocks
10 cheap wide-moat US stocks for 2025
Undervalued high-quality names from the Morningstar Wide Moat Focus Index are attractive stocks to buy for long-term investors.
stocks
10 best US blue-chip stocks to buy for the long term
The stocks of these high-quality companies with large market capitalisations look undervalued today.
personal-finance
US stock market outlook: tariffs are 2025's wild card
Macrodynamic tailwinds persist, but stocks are already priced to perfection. Will tariffs derail the market in 2025?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,841.90 | 8.30 | 0.09% |
CAC 40 | 7,696.27 | 58.28 | -0.75% |
DAX 40 | 23,787.45 | 146.68 | -0.61% |
Dow JONES (US) | 44,828.53 | 344.11 | 0.77% |
FTSE 100 | 8,822.91 | 0.29 | -0.00% |
HKSE | 23,916.06 | 153.88 | -0.64% |
NASDAQ | 20,601.10 | 207.97 | 1.02% |
Nikkei 225 | 39,810.88 | 24.98 | 0.06% |
NZX 50 Index | 12,766.60 | 62.12 | 0.49% |
S&P 500 | 6,279.35 | 51.93 | 0.83% |
S&P/ASX 200 | 8,603.00 | 7.20 | 0.08% |
SSE Composite Index | 3,472.32 | 11.17 | 0.32% |